400-920-2911 sales@csnpharm.cn
您的位置 : 首页 / PI3K/Akt/mTOR / PI3K / Duvelisib
CAS No.: 1201438-56-3
Synonyms: IPI-145;INK1197;IPI-145. INK1197
Duvelisib is a selective PI3K δ/γ inhibitor with Ki and IC50 of 23 pM/243 pM and 1 nM/50 nM, highly selective for PI3K δ/γ than other protein kinases.
生物活性
靶点 | PI3Kγ IC50:50nM | PI3Kδ IC50:1nM |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|---|---|---|---|---|
NCT02158091 | Chronic Lymphocytic Leukemia | Phase 1 Phase 2 | Active, not recruiting | July 2021 | United States, Massachusetts ... more >> Beth Isreal Deaconess Medical Center Boston, Massachusetts, United States, 02115 Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 Collapse << |
NCT01925911 | Healthy | Phase 1 | Completed | - | United States, Kansas ... more >> PRA International Lenexa, Kansas, United States, 66219 Collapse << |
NCT03757000 | B-cell Lymphoma Recurrent ... more >> B-cell Chronic Lymphocytic Leukemia Collapse << | Phase 1 | Recruiting | May 30, 2019 | China, Beijing ... more >> Peking Cancer Hospital Recruiting Beijing, Beijing, China, 100142 Contact: Yuqin Song, MD,PhD 86 10-88140650 songyuqin622@163.com Contact: Meifeng Tu, MD,PhD 86 10-88121122 44329472@qq.com Principal Investigator: Yuqin Song, MD,PhD Sub-Investigator: Meifeng Tu, MD,PhD Sub-Investigator: Lingyan Ping, MD,PhD China, Jiangsu Jiangsu Province Hospital Not yet recruiting Nanjing, Jiangsu, China, 210029 Contact: Jiangyong Li, MD,PhD 86 25-83714511 lijianyonglm@126.com Contact: Wei Xu, MD,PhD 86 25-83714511 xuwei0484@jsph.org.cn Principal Investigator: Jianyong Li, MD,PhD Sub-Investigator: Meifeng Tu, MD,PhD China, Tianjin Hematology Hospital of Chinese Academy of Medical Sciences Recruiting Tianjin, Tianjin, China, 300020 Contact: Lugui Qiu, MD,PhD 86 22-23909172 qiulg@ihcams.ac.cn Contact: Junyuan Qi, MD,PhD 86 22-23909999 qijy@ihcams.ac.cn Principal Investigator: Lugui Qiu, MD,PhD Sub-Investigator: Junyuan Qi, MD,PhD Collapse << |
实验方案
技术信息
CAS号 | 1201438-56-3 | 储存条件 |
|
|||||||
分子式 | C22H17ClN6O | 运输 | 蓝冰 | |||||||
分子量 | 416.86 | 别名 | IPI-145;INK1197;IPI-145. INK1197;Copiktra。 | |||||||
溶解度 |
|
动物实验配方 |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|
NCT02158091 | Chronic Lymphocytic Leukemia | Phase 1 Phase 2 | Active, not recruiting | July 2021 | United States, Massachusetts ... more >> Beth Isreal Deaconess Medical Center Boston, Massachusetts, United States, 02115 Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 Collapse << |
NCT01925911 | Healthy | Phase 1 | Completed | - | United States, Kansas ... more >> PRA International Lenexa, Kansas, United States, 66219 Collapse << |
NCT03757000 | B-cell Lymphoma Recurrent ... more >> B-cell Chronic Lymphocytic Leukemia Collapse << | Phase 1 | Recruiting | May 30, 2019 | China, Beijing ... more >> Peking Cancer Hospital Recruiting Beijing, Beijing, China, 100142 Contact: Yuqin Song, MD,PhD 86 10-88140650 songyuqin622@163.com Contact: Meifeng Tu, MD,PhD 86 10-88121122 44329472@qq.com Principal Investigator: Yuqin Song, MD,PhD Sub-Investigator: Meifeng Tu, MD,PhD Sub-Investigator: Lingyan Ping, MD,PhD China, Jiangsu Jiangsu Province Hospital Not yet recruiting Nanjing, Jiangsu, China, 210029 Contact: Jiangyong Li, MD,PhD 86 25-83714511 lijianyonglm@126.com Contact: Wei Xu, MD,PhD 86 25-83714511 xuwei0484@jsph.org.cn Principal Investigator: Jianyong Li, MD,PhD Sub-Investigator: Meifeng Tu, MD,PhD China, Tianjin Hematology Hospital of Chinese Academy of Medical Sciences Recruiting Tianjin, Tianjin, China, 300020 Contact: Lugui Qiu, MD,PhD 86 22-23909172 qiulg@ihcams.ac.cn Contact: Junyuan Qi, MD,PhD 86 22-23909999 qijy@ihcams.ac.cn Principal Investigator: Lugui Qiu, MD,PhD Sub-Investigator: Junyuan Qi, MD,PhD Collapse << |
NCT01549106 | Healthy Volunteers | Phase 1 | Completed | - | Netherlands ... more >> PRA International Zuidlaren, Netherlands, 9470 AE Collapse << |
NCT01947777 | Healthy | Phase 1 | Completed | - | United States, Kansas ... more >> PRA International, Inc Lenexa, Kansas, United States, 66219 Collapse << |
NCT02158091 | - | - | Active, not recruiting | - | - |
NCT02605694 | Lymphoma | Phase 2 | Withdrawn(Sponsor is focusing ... more >>on studies which can enable registration of duvelisib) Collapse << | - | United States, Florida ... more >> Miami, Florida, United States, 33133 Collapse << |
NCT01653756 | Asthma | Phase 2 | Completed | - | Germany ... more >> Investigational Site Berlin, Germany Investigational Site Grosshansdorf, Germany Investigational Site Wiesbaden, Germany United Kingdom Investigational Site Harrow, United Kingdom Collapse << |
NCT01851707 | Rheumatoid Arthritis | Phase 2 | Completed | - | - |
NCT02028039 | Leukemia | Phase 2 | Withdrawn | - | - |
NCT01836861 | Healthy | Phase 1 | Completed | - | Netherlands ... more >> Pharmaceuticals Research Association (PRA) Zuidlaren, Netherlands Collapse << |
NCT02049515 | Chronic Lymphocytic Leukemia ... more >> Small Lymphocytic Lymphoma Collapse << | Phase 3 | Enrolling by invitation | June 2019 | - |
NCT02204982 | Follicular Lymphoma | Phase 3 | Terminated(Sponsor is focusing... more >> on studies which can enable registration of duvelisib) Collapse << | - | Australia, Victoria ... more >> Frankston, Victoria, Australia, 3199 France Bordeaux, France, 33076 Italy Bologna, Italy, 40138 Terni, Italy, 05100 Poland Gdynia, Poland, 81-519 Collapse << |
NCT01871675 | Lymphoma Chro... more >>nic Lymphocytic Leukemia Non-Hodgkin Lymphoma T-cell Lymphoma Collapse << | Phase 1 | Completed | - | United States, Colorado ... more >> The Colorado Blood Cancer Institute Denver, Colorado, United States, 80218 United States, Florida Florida Cancer Specialists Sarasota, Florida, United States, 34232 United States, Oklahoma Oklahoma University Oklahoma City, Oklahoma, United States, 73104 United States, Tennessee Tennessee Oncology, PLLC Nashville, Tennessee, United States, 37203 Collapse << |
NCT02004522 | Chronic Lymphocytic Leukemia ... more >> Small Lymphocytic Lymphoma Collapse << | Phase 3 | Active, not recruiting | June 2021 | - |
NCT01476657 | Hematologic Malignancies | Phase 1 | Terminated(The scope of the pr... more >>ogram has been reduced to focus resources on studies which can potentially enable the registration of duvelisib.) Collapse << | - | United States, New York ... more >> New York, New York, United States, 10065 United States, Ohio Columbus, Ohio, United States, 43210 United States, Tennessee Nashville, Tennessee, United States, 37203 United States, Texas Houston, Texas, United States, 77030 Collapse << |
NCT02292225 | Lymphocytic Leukemia, Chronic ... more >> Lymphoma, Small Lymphocytic Collapse << | Phase 1 | Terminated(The scope of the pr... more >>ogram has been reduced to focus resources on studies which can potentially enable the registration of duvelisib.) Collapse << | - | United States, California ... more >> La Jolla, California, United States, 92093 United States, Massachusetts Boston, Massachusetts, United States, 02115 United States, New Jersey Hackensack, New Jersey, United States, 07601 United States, New York New Hyde Park, New York, United States, 11042 United States, Ohio Columbus, Ohio, United States, 43210 United States, Texas Houston, Texas, United States, 77030 Canada, Quebec Montreal, Quebec, Canada, H3T 1E2 Collapse << |
NCT02307461 | Healthy | Phase 1 | Completed | - | United States, Kansas ... more >> Lenexa, Kansas, United States, 66219 Collapse << |
NCT02391545 | CD20+ Follicular Lymphoma | Phase 1 Phase 2 | Completed | - | United States, California ... more >> Los Angeles, California, United States, 90095 Palo Alto, California, United States, 94304 United States, New Jersey Hackensack, New Jersey, United States, 07601 United States, New York Rochester, New York, United States, 14642 United States, Texas Dallas, Texas, United States, 75246 Belgium Kortrijk, Belgium, 8000 Leuven, Belgium, 3000 Wilrijk, Belgium, 2610 France Clermont-Ferrand, France, 63003 Marseille Cedex 05, France, 13385 Pessac, France, 33600 Rouen Cedex 1, France, 76038 Tours Cedex 01, France, 37044 Italy Bologna, Italy, 40138 Varese, Italy, 21100 Spain Badalona, Barcelona, Spain, 8916 Barcelona, Spain, 8097 Madrid, Spain, 28222 Salamanca, Spain, 37007 United Kingdom Leeds, United Kingdom, LS9 7TF London, United Kingdom, NW1 1BU Collapse << |
NCT02576275 | Indolent Non-Hodgkin's Lymphom... more >>a Follicular Lymphoma Small Lymphocytic Lymphoma Marginal Zone Lymphoma Collapse << | Phase 3 | Withdrawn(The scope of the pro... more >>gram has been reduced to focus resources on studies which can potentially enable the registration of duvelisib.) Collapse << | - | United States, Connecticut ... more >> Plainville, Connecticut, United States, 06062 United States, Florida Plantation, Florida, United States, 33322 United States, Georgia Thomasville, Georgia, United States, 31792 United States, New York East Setauket, New York, United States, 11733-3456 United States, Tennessee Cookeville, Tennessee, United States, 38501 Knoxville, Tennessee, United States, 37909 United States, Washington Spokane, Washington, United States, 99208 Collapse << |
NCT02640833 | Chronic Lymphocytic Leukemia ... more >> Small Lymphocytic Lymphoma Non-Hodgkin Lymphoma Collapse << | Phase 1 | Withdrawn(Study Stopped) | February 2021 | United States, Arizona ... more >> Site Reference ID/Investigator# 145677 Tucson, Arizona, United States, 85724-5024 United States, Illinois Site Reference ID/Investigator# 147922 Chicago, Illinois, United States, 60611 Site Reference ID/Investigator# 148562 Harvey, Illinois, United States, 60426 United States, Indiana Site Reference ID/Investigator# 148561 Goshen, Indiana, United States, 46526 United States, Maryland Site Reference ID/Investigator# 145674 Baltimore, Maryland, United States, 21287 United States, Massachusetts Site Reference ID/Investigator# 145145 Boston, Massachusetts, United States, 02215 United States, Michigan Site Reference ID/Investigator# 148010 Detroit, Michigan, United States, 48202 United States, Missouri Site Reference ID/Investigator# 147747 St. Louis, Missouri, United States, 63110 United States, New Hampshire Site Reference ID/Investigator# 145146 Lebanon, New Hampshire, United States, 03756 United States, South Carolina Site Reference ID/Investigator# 148559 Greenville, South Carolina, United States, 29605 Collapse << |
NCT02783625 | Lymphoma Rela... more >>psed/Refractory T-cell Lymphomas Collapse << | Phase 1 | Recruiting | May 2019 | United States, California ... more >> Stanford University Medical Center Recruiting Stanford, California, United States, 94305-5408 Contact: Youn Kim, MD 650-498-6000 United States, Massachusetts Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02115 Contact: Eric Jacobsen, MD 617-582-9086 United States, Missouri University of Washington School of Medicine in St. Louis Recruiting Saint Louis, Missouri, United States, 63110 Contact: Neha Mehta-Shah, MD 314-362-5654 Principal Investigator: Neha Mehta-Shah, MD Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: Neha Mehta-Shah, MD 314-362-5654 Principal Investigator: Neha Mehta-Shah, MD United States, New Jersey Memoral Sloan Kettering Cancer Center Basking Ridge Recruiting Basking Ridge, New Jersey, United States Contact: Steven Horwitz, MD 212-639-3045 Memorial Sloan Kettering Monmouth Recruiting Middletown, New Jersey, United States, 07748 Contact: Steven Horwitz, MD 212-639-3045 United States, New York Memorial Sloan Kettering Cancer Center @ Commack Recruiting Commack, New York, United States, 11725 Contact: Steven Horwitz, MD 212-639-3045 Memoral Sloan Kettering Westchester Recruiting Harrison, New York, United States Contact: Steven Horwitz, MD 212-639-3045 Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Steven Horwitz, MD 212-639-3045 Contact: Alison Moskowitz, MD 212-639-4839 Principal Investigator: Steven Horwitz, MD Memorial Sloan Kettering at Mercy Medical Center Recruiting Rockville Centre, New York, United States Contact: Steven Horwitz, MD 212-639-3045 Collapse << |
NCT03372057 | Peripheral T-cell Lymphoma | Phase 2 | Recruiting | December 2021 | United States, California ... more >> City of Hope National Medical Center Recruiting Duarte, California, United States, 91010 Contact: Rosemarie Abary 626-218-8087 rabary@coh.org Principal Investigator: Jasmine Zain, MD United States, Illinois Northwestern University - Feinberg School of Medicine Recruiting Chicago, Illinois, United States, 60611 Contact: Nick Cornicelli 312-695-0706 nicholas.cornicelli@northwestern.edu Principal Investigator: Barbara Pro, MD United States, Massachusetts Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Erin Jeter 617-632-6218 Erin_Jeter@DFCI.HARVARD.EDU Principal Investigator: Eric Jacobsen, MD United States, Missouri Washington University Recruiting Saint Louis, Missouri, United States, 63110 Contact: Kristen McDaniels, BS 314-747-1207 k.mcdaniels@wustl.edu Principal Investigator: Neha Mehta-Shah, MD United States, New York Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10021 Contact: Nasrin Ahmed 646-449-1311 ahmedn1@mskcc.org Principal Investigator: Steven Horwitz, MD University of Rochester Recruiting Rochester, New York, United States, 14627 Contact: Yelena Lerman 585-276-8333 ylerman@urmc.rochester.edu Contact: Erin Cebula erin_cebula@urmc.rochester.edu Principal Investigator: Carla Casulo, MD United States, Ohio The Ohio State Univeristy Recruiting Columbia, Ohio, United States, 43202 Contact: Pamela Heeter 614-293-9627 pam.heeter@osumc.edu Principal Investigator: Jonathan Brammer, MD Collapse << |
NCT02095587 | Hepatic Impairment | Phase 1 | Completed | - | United States, Florida ... more >> Miami, Florida, United States, 33014 Collapse << |
NCT03370185 | Chronic Lymphocytic Leukemia ... more >> Small Lymphocytic Lymphoma Collapse << | Phase 2 | Suspended(Reassessing corporat... more >>e priorities.) Collapse << | March 2021 | United States, Arizona ... more >> Arizona Oncology Tempe, Arizona, United States, 85284 United States, Arkansas Genesis Cancer Center Hot Springs, Arkansas, United States, 71913 United States, California Moores UC San Diego Cancer Center La Jolla, California, United States, 92093 United States, Illinois Ingalls Memorial Hospital Harvey, Illinois, United States, 60426 United States, Michigan QUEST Research Institute Royal Oak, Michigan, United States, 48073 United States, Montana St. Vincent Frontier Cancer Center Billings, Montana, United States, 59102 United States, New Jersey Summit Medical Group Morristown, New Jersey, United States, 07932 United States, Washington Medical Oncology Associates PS, WA Spokane, Washington, United States, 99208 Collapse << |
NCT03534323 | Chronic Lymphocytic Leukemia | Phase 1 Phase 2 | Recruiting | June 1, 2024 | United States, Massachusetts ... more >> Massachusetts General Hospital Not yet recruiting Boston, Massachusetts, United States, 02114 Contact: Jacob Soumerai, MD 617-726-2865 jsoumerai@mgh.harvard.edu Beth Israel Deaconess Medical Center Not yet recruiting Boston, Massachusetts, United States, 02215 Contact: Jon Arnason, MD 617-667-9920 jarnason@bidmc.harvard.edu Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Karen Francoeur, RN 617-632-5849 kalowe@partners.org Principal Investigator: Mattherw S Davids, MD Collapse << |
NCT01882803 | - | - | Active, not recruiting | - | - |
NCT02711852 | Hematologic Malignancy | Phase 2 | Active, not recruiting | December 2020 | United States, Colorado ... more >> Denver, Colorado, United States, 80218 United States, Florida Sarasota, Florida, United States, 34232 United States, Tennessee Nashville, Tennessee, United States, 37203 United States, Texas UT MD Anderson Cancer Center Houston, Texas, United States, 77030 Italy Azienda Ospedaliera Santa Maria di Terni/SC Oncoematologia Terni, Umbria, Italy, 05100 Collapse << |
NCT02598570 | Lymphoma | Phase 1 | Completed | - | Japan ... more >> Site Reference ID/Investigator# 141826 Aichi, Japan Site Reference ID/Investigator# 141595 Fukuoka, Japan Site Reference ID/Investigator# 141594 Tokyo, Japan Collapse << |
NCT01882803 | Indolent Non-Hodgkin Lymphoma | Phase 2 | Active, not recruiting | October 20, 2021 | - |
靶点 | Description | IC50 |
---|---|---|
PI3Kγ | IC50:50nM | |
PI3Kδ | IC50:1nM |
联系我们
官方电话:400-920-2911
二维码
微信公众号 CSN官网